News

New investors include Sofinnova, Vivo Capital, F-Prime Capital Partners, certain investment funds advised by Clough Capital Partners L.P., and venBio Select. Existing investors Morningside Ventures, Cormorant Asset Management,

Gilead filed the NDA for BIC/FTC/TAF with a Priority Review voucher on June 12, 2017, and FDA has set a target action date under the Prescription Drug User

Under the terms of the transaction, the parties will enter into a long-term supply agreement for Perrigo API to supply its inventory of existing commercial and pipeline APIs

Under the revised terms, the option to acquire Sutro has been ceased along with limitations from Sutro entering into additional collaborations or accessing the public financial markets. The

"We are pleased that the FDA has granted orphan-drug designation for cobitolimod for treatment of ulcerative colitis in children, which may provide seven years of market exclusivity in

General agreement was reached with the FDA on the design and key elements for HTX-011’s Phase 3 program that will be required to support a New Drug Application

Dubbed DEL MAR stage 2, the phase 2b stage 2 clinical trial assessed the performance of Luminate as either a sequential therapy or in combination with anti-VEGF in 80

Tb535H, which is an anti-5T4 pan-cancer T-cell engager, will get support from the Cancer Research UK in its early clinical development. The first-in-class Fdrug is evolved from Biotecnol’s

Cardioxane is an oncology support drug that prevents chronic cumulative cardiotoxicity caused by high dose anthracycline chemotherapy. In 1992, it was licensed for international markets but its label